Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 17, 2022 16:01 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences Reports Fourth Quarter and Full Year 2021 Results

– YUSIMRY™ (adalimumab-aqvh), Coherus’ second product, approved by FDA on December 17, 2021 –– BLAs under FDA review for PD-1 inhibitor toripalimab and CIMERLI™ (ranibizumab-ranq) –– New FDA filings...
February 15, 2022 16:30 ET | Source: Coherus BioSciences, Inc.

Coherus Names Paul Reider Chief Commercial Officer

REDWOOD CITY, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) today announced Paul Reider has been named Chief Commercial Officer. Mr....
February 14, 2022 08:30 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective Feb. 9, 2022, the compensation committee...
February 11, 2022 08:30 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 17th, 2022

REDWOOD CITY, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its fourth quarter and full year 2021 financial results will be...
February 07, 2022 08:30 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences Appoints Health Care Payer Expert Lee N. Newcomer, M.D., to Board of Directors

REDWOOD CITY, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS) today announced the appointment of board-certified oncologist and...
January 10, 2022 07:30 ET | Source: Coherus BioSciences, Inc.

Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody

• Coherus and Junshi Biosciences plan to evaluate the toripalimab + JS006 combinationin clinical trials in multiple tumor types • Combinations of PD-1 + TIGIT inhibitors have potential to expand...
January 07, 2022 08:30 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences Secures Credit Financing with Pharmakon Advisors

REDWOOD CITY, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company) (Nasdaq: CHRS) today announced that it has entered into a loan agreement with investment...
January 04, 2022 08:32 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences Management to Present at the 40th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 40th Annual J.P....
December 20, 2021 07:59 ET | Source: Coherus BioSciences, Inc.

Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)

- Approved for all eligible indications of the reference biological product, Humira® (adalimumab) - - YUSIMRY is Coherus' second FDA-approved product - REDWOOD CITY, Calif., Dec. 20, 2021 (GLOBE...
December 17, 2021 09:09 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development Officer

REDWOOD CITY, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Theresa LaVallee, Ph.D. as its Chief Development Officer. Dr....